Work

Immune biomarkers and treatment (tx) outcome in hormone receptor-positive (HR+) breast cancer (BC) patients (pts) treated with preoperative chemotherapy (preop chemo) plus bevacizumab (bev).

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.e12134

Authors: Adrienne Gropper Waks, William Thomas Barry, Evisa Gjini, Deborah Dillon, Scott Rodig, Jane E. Brock, Michele Baltay, Jennifer Savoie, Daniel G. Stover, Eric P. Winer, Ian E. Krop, Sara M. Tolaney

Institutions: Dana-Farber Cancer Institute, Brigham and Women's Hospital

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2624139209

Cites:

Cited by: 1

Related to: 10